InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX Clue Score53
United States Fiscal year ends December CIK 0001341235
$0.92 -3.31% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.92 −89.30% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 11 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2016Operating income−18.7Net income−18.7Fiscal year 2017Operating income−22.5Net income−22.3Fiscal year 2018Operating income−39.7Net income−38.9Fiscal year 2019Operating income−63.1Net income−60.8Fiscal year 2020Operating income−36.4Net income−37.6Fiscal year 2021Operating income−56.2Net income−57.8EPS, diluted−1.07Fiscal year 2022Operating income−62.7Net income−62.0EPS, diluted−1.06Fiscal year 2023Operating income−42.8Net income−37.5EPS, diluted−0.64Fiscal year 2024Operating income−60.1Net income−55.9EPS, diluted−0.94Fiscal year 2025Operating income−35.3Net income−33.8EPS, diluted−0.56
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −18.7 −22.5 −39.7 −63.1 −36.4 −56.2 −62.7 −42.8 −60.1 −35.3
Net income −18.7 −22.3 −38.9 −60.8 −37.6 −57.8 −62.0 −37.5 −55.9 −33.8
Growth
EPS, diluted n/a n/a n/a n/a n/a −1.07 −1.06 −0.64 −0.94 −0.56
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−15.1Capital expenditure−0.0Free cash flow−15.2Fiscal year 2017Operating cash flow−19.2Capital expenditure−0.0Free cash flow−19.2Fiscal year 2018Operating cash flow−29.9Capital expenditure−0.3Free cash flow−30.1Fiscal year 2019Operating cash flow−45.0Capital expenditure−0.0Free cash flow−45.0Fiscal year 2020Operating cash flow−37.5Fiscal year 2021Operating cash flow−42.6Capital expenditure−0.0Free cash flow−42.6Fiscal year 2022Operating cash flow−56.6Capital expenditure−0.0Free cash flow−56.7Fiscal year 2023Operating cash flow−30.3Capital expenditure0.0Free cash flow−30.3Fiscal year 2024Operating cash flow−43.2Fiscal year 2025Operating cash flow−33.3
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −15.1 −19.2 −29.9 −45.0 −37.5 −42.6 −56.6 −30.3 −43.2 −33.3
Capital expenditure −0.0 −0.0 −0.3 −0.0 n/a −0.0 −0.0 0.0 n/a n/a
Free cash flow −15.2 −19.2 −30.1 −45.0 n/a −42.6 −56.7 −30.3 n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2016Cash12.0Total debt1.3Net cash (debt)10.7Shareholders’ equity21.6Debt to equity0.06Fiscal year 2017Cash20.0Total debt1.3Net cash (debt)18.7Shareholders’ equity39.6Debt to equity0.03Fiscal year 2018Cash47.4Total debt16.0Net cash (debt)31.3Shareholders’ equity86.6Debt to equity0.19Fiscal year 2019Cash44.4Total debt14.5Net cash (debt)29.9Shareholders’ equity48.1Debt to equity0.30Fiscal year 2020Cash77.9Total debt11.4Net cash (debt)66.4Shareholders’ equity59.5Debt to equity0.19Fiscal year 2021Cash229.8Total debt15.5Net cash (debt)214.3Shareholders’ equity205.7Debt to equity0.08Fiscal year 2022Cash144.4Total debt15.8Net cash (debt)128.6Shareholders’ equity151.0Debt to equity0.10Fiscal year 2023Cash142.8Total debt15.1Net cash (debt)127.7Shareholders’ equity119.8Debt to equity0.13Fiscal year 2024Cash54.5Total debt15.0Net cash (debt)39.5Shareholders’ equity71.0Debt to equity0.21Fiscal year 2025Cash70.0Total debt15.2Net cash (debt)54.8Shareholders’ equity44.3Debt to equity0.34
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 12.0 20.0 47.4 44.4 77.9 229.8 144.4 142.8 54.5 70.0
Total debt 1.3 1.3 16.0 14.5 11.4 15.5 15.8 15.1 15.0 15.2
Net cash (debt) 10.7 18.7 31.3 29.9 66.4 214.3 128.6 127.7 39.5 54.8
Shareholders’ equity 21.6 39.6 86.6 48.1 59.5 205.7 151.0 119.8 71.0 44.3
Debt to equity 0.06 0.03 0.19 0.30 0.19 0.08 0.10 0.13 0.21 0.34

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−15.1 −19.2 −29.9 −45.0 −37.5 −42.6 −56.6 −30.3 −43.2 −33.3
Growth
Investment
−0.0 −0.0 −0.3 −0.0 n/a −0.0 −0.0 0.0 n/a n/a
calc −15.2 −19.2 −30.1 −45.0 n/a −42.6 −56.7 −30.3 n/a n/a
Growth
calc n/a n/a n/a n/a n/a −0.79 −0.97 −0.51 n/a n/a
n/a −10.2 −23.3 18.5 29.0 −0.0 −30.0 30.0 −44.9 47.7
Financing
n/a 37.4 80.5 23.6 41.9 194.5 1.2 −1.3 −0.2 1.1

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.